Join Jo Daviess County Master Gardener Mike Iacomini for a program on “Tree Health” on Tuesday, May 27 at 1:30 p.m. at the Jo Daviess County Extension Office, 204 N. Vine Street, Elizabeth, IL. There ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk (NVO) is not a stock that is constantly staring at me from my screen, hoping I will get its attention. I like the Dow 30 and maybe another 20 stocks. I will consider just about ...

Saif will soon be seen in Netflix's Jewel Thief: The Heist Begins, and fans cannot keep calm anymore. At a recent interview, Saif's co-stars Jaideep Ahlawat and Kunal Kapoor shared their experience of ...

Lisa Montgomery and Bobbie Jo Stinnett met at a dog show and shared a passion for breeding. But when Lisa came to visit, their connection turned deadly File Photo What began as an ordinary visit ...

Following the release of encouraging news about an oral weight-loss medication by rival Eli Lilly (LLY), shares of Novo Nordisk (NVO), which is listed in the United States, fell 7% during intraday ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...

Elizabeth Pennell alleges that Novo Nordisk A/S, the drug’s manufacturer, should have been aware of the potential risk of blindness associated with the medication. Pennell, who was using Ozempic to ...

Unfortunately, what's good news for Eli Lilly is probably bad news for investors in Novo Nordisk and Viking Therapeutics, both of which lag Lilly in the race to develop their own easy-to-take GLP ...

While the momentum for Lilly is accelerating, that for Novo is slowing. In 2024, Lilly and Novo grew by 32% and 26%, respectively. This year, the gulf between their growth is expected to widen ...